Published human trials
CJC-1295
GHRH analog, also called modified GRF(1-29). Short half-life relative to the DAC form.
Reference entry for CJC-1295 →Trial record
0 trials on fileNothing has been entered here yet.
That states what this record contains, not what the literature contains — we have not published a search of our own and will not imply one. The two converge as the record is built from PubMed, ClinicalTrials.gov, and Europe PMC, one compound at a time, with each entry checked against the source document before it appears.
Until then this page stays empty rather than approximate. Nothing gets summarized from memory, and no amount is written here to make CJC-1295 look better documented than it is.
An empty record is a reading
For several compounds in this catalog the published human work is genuinely thin — what exists is preclinical, in cell culture or in animals, and the count here will stay at or near zero permanently. That absence is often the most useful thing a reference page can tell you. A vendor that fills the space anyway has not found trials we missed; it has written something.
What gets added
A published study that reports what it administered, to whom, by what route, and for how long — with a link you can open. The source column is not null in the schema, so an entry without one cannot be stored. Preclinical work is not listed here, because a mouse dose printed next to a vial is a number waiting to be misread.
Standing note
This record reports what published studies did. It is not a recommendation, not medical advice, and not a protocol for use in humans. Amounts appear only as the source stated them, for the population and duration that source studied, and carry nothing over to anyone outside it. Nothing on this page is instructions.